What The Study Did: This study quantified changes in the use of intravitreal (IVT) anti-vascular endothelial growth factors (anti-VEGF), the main treatment for retinal vascular abnormalities, since the COVID-19 pandemic started in France.
Authors: Sophie Billioti de Gage, Pharm.D., P.D., of EPI-PHARE, French National Agency for Medicines and Health Products Safety, French National Health Insurance in Saint-Denis, France, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamaophthalmol.2020.5594)
Editor's Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
###
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaophthalmology/fullarticle/10.1001/jamaophthalmol.2020.5594?guestAccessKey=4c61f110-140e-479d-a7a6-6f2f22c034ad&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=121720
JAMA Ophthalmology